Location History:
- Seoul, KR (2011)
- Daejeon, KR (2013)
Company Filing History:
Years Active: 2011-2013
Title: Kyung Chul Cho: Innovator in Pharmaceutical Composition
Introduction
Kyung Chul Cho is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions aimed at preventing and treating vascular restenosis. With a total of 2 patents to his name, Cho's work is recognized for its potential impact on medical treatments.
Latest Patents
One of Cho's latest patents is a pharmaceutical composition for the prevention and treatment of restenosis comprising isoxazole derivatives. This composition includes a therapeutically effective amount of isoxazole derivatives represented by a specific formula or pharmaceutically available salts thereof. The composition is particularly useful in preventing and treating vascular restenosis due to its demonstrated anti-restenosis activity and ability to accelerate re-endothelization. Another notable patent involves isoxazole derivatives and their uses, which serve as agonists of Wnt. These derivatives activate Wnt/β-catenin signaling, making them applicable in the treatment and prevention of diseases related to this signaling pathway.
Career Highlights
Kyung Chul Cho has worked with notable companies such as SK Holdings Co., Ltd. and SK Biopharmaceuticals Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical innovations and research.
Collaborations
Cho has collaborated with several professionals in his field, including Jeong Woo Cho and Sang Rak Choi. These collaborations have likely enhanced his research and development efforts in pharmaceutical compositions.
Conclusion
Kyung Chul Cho is a distinguished inventor whose work in pharmaceutical compositions has the potential to advance medical treatments significantly. His contributions to the field, particularly through his patents, reflect his commitment to innovation in healthcare.